IMS 2026 highlights: advances in multiple myeloma treatment and the path towards cure
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
IMS 2026 highlights: advances in multiple myeloma treatment and the path towards cure
-
ナレーター：
-
著者：
In this episode of the VJHemOnc podcast, leading experts discuss key advances in multiple myeloma presented at the 23rd Annual Meeting and Exposition of the International Myeloma Society (IMS 2026), held in Glasgow, UK. Pieter Sonneveld reviews long-term progression-free survival outcomes from the Phase III PERSEUS trial (NCT03710603), while Zachary Avigan explores the potential for treatment cessation in patients with sustained measurable residual disease (MRD) negativity and the evolving concept of cure. Rakesh Popat discusses emerging combination strategies at first relapse, and Luciano Costa examines the survival benefits of teclistamab plus daratumumab in the Phase III MajesTEC-3 trial (NCT05083169). Hermann Einsele highlights real-world and long-term outcomes with ciltacabtagene autoleucel (cilta-cel), Shaji Kumar discusses the Phase III CERVINO trial of etentamig, and Paul Richardson explores the evolving role of cereblon E3 ligase modulators (CELMoDs). Together, these experts consider how advances in immunotherapy, novel agents, and treatment sequencing may shape the future management of patients with multiple myeloma.